EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial

Karim Fizazi, Matthew R Smith, Maha Hussain, Fred Saad, Cora N Sternberg, E David Crawford, Jeanny B Aragon-Ching, Martin Schostak, Ronald Tutrone, Alicia K Morgans, Daniel Sentana-Lledo, Heikki Joensuu und 7 weitere

European Journal of Cancer · 2026-08 · 244 · 116888

DOI: 10.1016/j.ejca.2026.116888 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Cancer, 2026-08. Verfasst von Karim Fizazi und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cancer Medicine, Centre Oscar Lambret, Institute Gustave Roussy, University of Paris-Saclay, Lille, France. Electronic address: k-fizaz…. Hauptthemen laut MEDLINE: Quality of Life, Prostatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Androgen Receptor Antagonists. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bayer Healthcare, Bayer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeProstatic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAndrogen Receptor AntagonistsHumansMaleAgedDocetaxelMiddle AgedDouble-Blind MethodTreatment OutcomeAndrogen AntagonistsPyrazoles

Stichwörter der Autor:innen

DarolutamideHealth-related quality of lifeMetastatic hormone-sensitive prostate cancerPainSafety

Substanzen

darolutamideDocetaxelAndrogen Receptor AntagonistsAndrogen AntagonistsPyrazoles

Autor:innen und Institutionen

  • Department of Cancer Medicine, Centre Oscar Lambret, Institute Gustave Roussy, University of Paris-Saclay, Lille, France. Electronic address: k-fizazi@o-lambret.fr.
  • Genitourinary Oncology Program, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, MA, USA.
  • Division of Hematology-Oncology, Department of Medicine, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Department of Urology, University of Montreal Hospital Center, Montreal, QC, Canada.
  • Englander Institute for Precision Medicine, Weill Cornell Department of Medicine, Meyer Cancer Center, New York-Presbyterian Hospital, Hematology/Oncology, New York, NY, USA.
  • Department of Urology, UC San Diego School of Medicine, La Jolla, CA, USA.

Förderung

  • Bayer Healthcare
  • Bayer

Zitieren

APA

Fizazi, K., Smith, M. R., Hussain, M., Saad, F., Sternberg, C. N., David Crawford, E., Aragon-Ching, J. B., Schostak, M., Tutrone, R., Morgans, A. K., Sentana-Lledo, D., Joensuu, H., Mohamed, A. F., Littleton, N., Srinivasan, S., Buttkewitz, Y., Li, R., Kuss, I., & Tombal, B. (2026). Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. European Journal of Cancer, 244, 116888. https://doi.org/10.1016/j.ejca.2026.116888

Vancouver

Fizazi K, Smith MR, Hussain M, Saad F, Sternberg CN, David Crawford E, et al. Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial. European Journal of Cancer. 2026;244:116888. doi:10.1016/j.ejca.2026.116888

BibTeX
@article{Fizazi2026,
  author = {Fizazi, Karim and Smith, Matthew R and Hussain, Maha and Saad, Fred and Sternberg, Cora N and David Crawford, E and Aragon-Ching, Jeanny B and Schostak, Martin and Tutrone, Ronald and Morgans, Alicia K and Sentana-Lledo, Daniel and Joensuu, Heikki and Mohamed, Ateesha F and Littleton, Natasha and Srinivasan, Shankar and Buttkewitz, Yvonne and Li, Rui and Kuss, Iris and Tombal, Bertrand},
  title = {Clinically relevant endpoints and quality-of-life outcomes with darolutamide in patients with metastatic hormone-sensitive prostate cancer: Analyses of the phase III ARASENS trial},
  journal = {European Journal of Cancer},
  year = {2026},
  volume = {244},
  pages = {116888},
  doi = {10.1016/j.ejca.2026.116888}
}
Kostenlos starten →